28.80
+26.3(+1052.00%)
Currency In USD
Address
10170 Church Ranch Way
Westminster, CO 80021
United States of America
Phone
720 940 2200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
August 08, 1997
| Name | Title | Pay | Year Born |
| Mr. C. Jeffrey Dekker CPA | Chief Financial Officer, Treasurer & Company Secretary | 323,072 | 1965 |
| Mr. Thomas A. Keuer | President, Chief Operating Officer & Principal Executive Officer | 400,802 | 1959 |
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
